Brand Name(s): Regranex
CAS nº: 165101-51-9
(be-kap-ler-min)
About Becaplermin
This new site is dedicated exclusively to becaplermin.
It provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.
Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about becaplermin on this reference site, as well as take part in our open discussion forum by sharing your own knowledge and experience with people who are using this medication.
This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total becaplermin experience!
Why is this medication prescribed?
Becaplermin is used to treat ulcers of the foot, ankle, or leg in patients with diabetes.
This medicine is a human platelet-derived growth factor, a substance naturally produced by the body that helps in wound healing. It works, in combination with good ulcer care (cleaning, pressure relief, and infection control), by bringing the cells that the body uses to repair wounds to the site of the ulcer.
Latest News
Cardium Acquires Excellarate Product Candidate for Chronic Diabetic Ulcers and Related Technology and Assets From Tissue Repair Company
Cardium Therapeutics, Inc. (Bulletin board: CDTP) today announced its acquisition of the wound...
[more]Regranex® (Becaplermin) Gel Is Effective Treatment Of Diabetic Neuropathic Foot Ulcers, Study Confirms
Johnson & Johnson Wound Management, a division of ETHICON, INC., today announced the publication of...
[more]Recent Study Confirms REGRANEX® (Becaplermin) Gel To Be Effective Treatment Of Diabetic Neuropathic Foot Ulcers
Somerville, NJ – Johnson & Johnson Wound Management, a division of ETHICON, INC., today announced...
[more]Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor
The author set forth to further assess the responsiveness of hemangioma ulceration to 0.01%...
[more]